Separately, analysts at Stifel Nicolaus downgraded shares of Sophiris Bio from a “buy” rating to a “hold” rating and set a $7.00 price target on the stock in a research note on Thursday, December 18th.
Will go through $2.50 it should have been at $7's after initial NDA approval. FDA gives it the go this time. Biggest Pharma % gainer here 2015. Buy and hold seems big players are accumulating. Volume. Parkinson's second driver.